Glucocorticoid excess and hypertension

Current Hypertension Reports

Volumn 6, Issue 6, 2004, Pages 493-499

  Baid, Smita ^a   Nieman, Lynnette K ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BOSENTAN; CAPTOPRIL; CORTICOSTERONE; CORTICOTROPIN; DEOXYCORTICOSTERONE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; LOSARTAN; MIFEPRISTONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; PREDNISONE; PROSTACYCLIN; RAMIPRIL; SARALASIN; SODIUM; SPIRONOLACTONE; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; TETRAHYDROCORTISOL; UNINDEXED DRUG; VASODILATOR AGENT; WATER;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CUSHING SYNDROME; HEART RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; METABOLIC SYNDROME X; MODULATION; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR SYSTEM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VASCULAR TISSUE; VASCULARIZATION;

EID: 10044223172     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0046-0     Document Type: Review

References (53)

1. Arnoldi G, Angeli A, Atkinson AB, et al.: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-5602.
2. Ross EJ, Linch DC: Cushing's syndrome - killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982, 2:646-649.
3. Stewart PM, Walker BR, Holder F: 11 beta-hydroxysteroid dehydrogense activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995, 80:3617-3620.
4. Magiakou MA, Mastorakos G, Zachman K, et al.: Blood pressure in children and adolescents with Cushing's syndrome before and after surgical cure. J Clin Endocrinol Metab 1997, 82: 734-1738.
5. Fraser R, Davies DL, Connell JMC: Hormones and hypertension. Clin Endocrinol 1989, 31:701-746.
6. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
7. Extabe J, Vazquez JA: Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479-484.
8. Torpy DJ, Mullen N, Ilias I, et al.: Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion. Ann N Y Acad Sci 2002, 970:134-144.
9. Faggiano A, Pivonello R, Spiezia S, et al.: Cardiovascular risk factors and common carotid artery caliber and stiffness inpatients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88:2527-2533.
10. Panarelli M, Terzolo M, Piovesan A, et al.: 24-hour profiles of blood pressure and heart rate in Cushing's syndrome: evidence for differential control of cardiovascular variables by glucocorticoids Ann Ital Med Int 1990, 5:18-25.
11. Zelinka T, Strauch B, Pecen L, et al.: Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 2004, 18:107-111.
12. Hatakeyama H, Inaba S, Miyamori I: 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in the development of hypertension. Hypertension 1999, 33: 179-1184.
13. Brem A, Bina R, King T, et al.: Localization of 2 11 beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31:459-462.
14. Ritchie CM, Sheridan B, Fraser R, et al.: Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990, 280:855-867.
15. Ulick S, Wang JZ, Blumenfeld JD, et al.: Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metabol 1992, 74:963-967.
16. Quinkler M, Stewart PM: Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003, 88: 384-2392.
17. Dotsch J, Dorr HG, Stall GK, et al.: Effect of glucocorticoid excess on the cortisol/cortisone ratio. Steroids 2001, 66:817-820.
18. Ferrari P, Krozowski Z: Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000, 57:1374-1381.
19. Farman N, Bocchi B: Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000, 57: 364-1369.
20. Connell JM, Whitworth JA, Davies DL, et al.: Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man J Hypertens 1987, 5:425-433.
21. Mangos GJ, Whitworth JA, Williamson PM: Glucocorticoids and the kidney. Nephrology 2003, 8:267-273.
22. Whitworth JA, Gordon D, Andrews J, et al.: The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537-549.
23. Nieman LK, Chrousos GP, Kellner C, et al.: Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985, 61: 36-540.
24. Sala C, Ambrosi B, Morganti A: Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing's disease. J Clin Endocrinol Metab 2001, 86: 957-1961.
25. Yasunari K, Kohno M, Murakawa K, et al.: Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle. Hypertension 1990, 16:581-586.
26. Kelm M: The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 2003, 5:80-86.
27. Axelrod L: Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1983, 23:904-906.
28. Saruta T, Suzuki H, Handa M, et al.: Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986, 62:275-279.
29. Scheuer DA, Becht AG: Glucocorticoids potentiate central actions of angiotensin to increase arterial pressure. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1719-R1726.
30. Pirpiris, M, Sudhir K, Yeung S, et al.: Pressor responsiveness in corticosteroid-induced hypertension in humans. J Hypertens 1989, 7:537-549.
31. McKnight JA, Rooney DP, Whitehead H, et al.: Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome. J Hum Hypertens 1995, 9:855-858.
32. Sato A, Suzuki H, Murakami M, et al.: Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994, 23:25-30.
33. Arai H, Hori S, Aramori I, et al.: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
34. Kirilov G, Tomova A, Dakovska L, et al.: Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003, 149: 49-553.
35. Quaschning T, Ruschitzka F, Niggli B, et al.: Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 2001, 16:2146-2151.
36. Shelat, SG, King JL, Flanagan-Cato LM, et al.: Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain. Neuroendocrinology 1999, 69:339-351.
37. Van Uum SH, Houben AJ, Hermus AR, et al.: Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. J Hypertens 2002, 20: 275-2283.
38. Zimmerman BG, Dunham EW.: Tissue renin-angiotensin system: A site of drug action? Ann Rev Pharmacol Toxicol 1997, 37: 3-69.
39. Nishiyama A, Fujisawa Y, Fukui T, et al.: Role of nitric oxide in regional blood flow in angiotensin II-induced hypertensive rats. Hypertens Res 2001, 24:421-427.
40. Souness GW, Brem AS, Morris DJ: 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002, 67:195-201.
41. Donmez G, Derici U, Erbas D, et al.: The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension Jpn J Physiol 2002, 52:435-440.
42. Tsikouris JP, Cox CD: Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 2003, 23:1141-1152.
43. Di Girolamo G, Gonzalez E, Livio D, et al.: The effect of enalapril on PGI(2) and NO levels in hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 2002, 66:493-498.
44. Yagi S, Morita T, Katayama S: Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004, 27:129-135.
45. Dalakos TG, Elias AN, Anderson GH Jr, et al.: Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome. J Clin Endocrinol Metab 1978, 46: 14-118.
46. Zacharieva S, Orbetzova M, Natchev E, et al.: Losartan in Cushing's syndrome. Methods Find Exp Clin Pharmacol 1998, 20:163-168.
47. Fallo F, Paoletta A, Tona F, et al.: Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J Intern Med 1993, 234:595-598.
48. Fallo F, Sonino N, Barzon L, et al.: Effect of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens 1996, 9:77-80.
49. Colao A, Pivonello R, Spiezia S, et al.: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84:2664-2672.
50. Seckl JR, Morton NM, Chapman KE, et al.: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue Recent Prog Horm Res 2004, 59:359-393.
51. Andrew R, Phillips DIW, Walker BR: Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998, 83:1806-1809.
52. Fraser R, Ingram MC, Anderson NH, et al.: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33:1364-1368.
53. Stewart PM, Boulton A, Kumar S, et al.: Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999, 84:1022-1027.